Enveric Hires Fish & Richardson To Defend IP Against Petition Claiming Its Patent Contains Claims Relevant To AbbVie's $1.2B Bretisilocin Acquisition - Enveric Biosciences (NASDAQ:ENVB), AbbVie (NYSE:ABBV)

Enveric Biosciences, Inc. (ENVB) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026 EB-003 Development Highlights: ● Continued advancing IND-enabling studies supporting the planned submission of an Investigational New Drug

AbbVie said its neuroscience franchise grew in 1H 2026, with sales of $6.1B, up 21.8% year over year on an operational basis. Vraylar led at $1.98B (+18.6%), with Ubrelvy $731M (+26.4%), Qulipta $646M (+39.2%), Botox $2.05B (+13.2%), and Vyalev $457M. AbbVie raised 2026 neuroscience guidance to about $12.7B (+$100M) and overall revenue to about $67.6B (+$300M). It expects an FDA decision on tavapadon for PD in 3Q 2026.

Genmab and AbbVie said the Phase 3 EPCORE DLBCL-1 trial of epcoritamab failed its U.S. overall survival primary endpoint, though the drug keeps accelerated FDA approval. Genmab reported H1 2026 revenue of $2.051B and raised 2026 guidance to $4.325–$4.525B. AbbVie reported Q2 2026 net revenues of $16.99B and EPS $3.65.

AbbVie (ABBV) reported Q1 2026 net revenues of $15.002B (+12.4% reported) and GAAP diluted EPS of $0.39, with adjusted diluted EPS of $2.65. AbbVie raised full-year 2026 adjusted EPS guidance to $14.08–$14.28. AbbVie’s Allergan Aesthetics said the EU approved Boey (trenibotulinumtoxinE) in all EEA countries. Canaccord raised its ABBV price target to $282.

Wolfe Research upgraded Biogen and AbbVie to Outperform, setting $300 price targets for each. For Biogen, it cited late-stage pipeline catalysts for litifilimab and felzartamab and said the Apellis acquisition strengthens near-term revenue. For AbbVie, it cited valuation, limited near-term loss-of-exclusivity risk, and multiple upcoming clinical catalysts.

Illinois Gov. JB Pritzker signed H.B. 2371, which limits drugmakers’ ability to restrict pharmacy contracting under the federal 340B Drug Pricing Program. AbbVie, Bristol Myers Squibb, and Novartis sued Illinois AG Kwame Raoul to block the law, arguing it conflicts with federal 340B rules and is unconstitutional. The companies seek a court declaration against the state law.